活体供肾移植治疗非典型溶血性尿毒症综合征:病例系列
该病例系列描述了17例非典型溶血性尿毒症综合征(aHUS)患者接受活体供肾移植后,采用仅对出现移植后复发性血栓性微血管病的受者使用依库珠单抗的方案,并强调降低他克莫司目标水平和积极治疗高血压。中位随访25个月,1例复发经依库珠单抗成功治疗,末次随访中位血清肌酐106 μmol/L,蛋白尿可忽略。结论认为不预防性使用依库珠单抗的活体供肾移植在aHUS中看似可行。
要点
- aHUS患者活体供肾移植可不预防性使用依库珠单抗,仅复发时治疗。
- 方案强调降低他克莫司目标水平和积极控制高血压。
- 中位随访25个月,1例复发经依库珠单抗成功治疗。
核心结论
- 不预防性使用依库珠单抗的活体供肾移植在aHUS中看似可行。
研究设计与样本
- 病例系列,纳入2011年后在2个大学中心接受活体供肾移植的aHUS患者,前瞻性随访。
主要发现
- 共17例患者,12例女性,5例男性,平均年龄47岁。
- 5例患者曾因aHUS复发失去既往移植物。
- 16例患者携带补体因子H、C3或膜辅因子蛋白基因的致病或可能致病性变异。
- 中位随访25个月(范围7-68个月),1例在移植后68天复发aHUS,经依库珠单抗成功治疗。
- 3例患者因排斥反应治疗,2例发生BK肾病;末次随访中位血清肌酐106 μmol/L(范围67-175),蛋白尿可忽略。
关键数值与推荐
- 依库珠单抗治疗仅限于有记录的移植后复发性血栓性微血管病的受者。
- 方案强调较低目标水平的他克莫司和积极治疗高血压。
临床怎么用
- 对于aHUS活体供肾移植受者,可考虑不预防性使用依库珠单抗,但需密切监测复发。
- 免疫抑制方案中建议降低他克莫司目标水平,并积极控制高血压。
局限性
- 样本量小且随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of complement inhibitors has greatly improved the outcome of patients with atypical hemolytic uremic syndrome (aHUS), making kidney transplantation a more feasible option. Although prophylactic eculizumab therapy may prevent recurrent disease after transplantation, its necessity for all transplant recipients is debated. STUDY DESIGN: A case series. SETTING & PARTICIPANTS: Patients with aHUS who underwent living donor kidney transplantation after 2011 at 2 university centers, prospectively followed up with a protocol of eculizumab therapy limited to only recipients with documented posttransplantation recurrent thrombotic microangiopathy. In addition, the protocol emphasized lower target level tacrolimus and aggressive treatment of high blood pressure. OUTCOMES: Recurrence of aHUS, kidney function, acute kidney injury. RESULTS: We describe 12 female and 5 male patients with a mean age of 47 years. 5 patients had lost a previous transplant due to aHUS recurrence. 16 patients carried a pathogenic or likely pathogenic variant in genes encoding complement factor H, C3, or membrane cofactor protein, giving a high risk for aHUS recurrence. Median follow-up after transplantation was 25 (range, 7-68) months. One patient had aHUS recurrence 68 days after transplantation, which was successfully treated with eculizumab. 3 patients were treated for rejection and 2 patients developed BK nephropathy. At the end of follow-up, median serum creatinine concentration was 106 (range, 67-175) μmol/L and proteinuria was negligible. LIMITATIONS: Small series and short duration of follow-up. CONCLUSIONS: Living donor kidney transplantation in aHUS without prophylactic eculizumab treatment appears feasible.
引用
- Duineveld C, Verhave JC, Berger SP, et al. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. Am J Kidney Dis. 2017. PMID: 28821363. doi:10.1053/j.ajkd.2017.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。